Id | Content |
---|---|
F1 | This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. |
F2 | This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date. |